After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
LILRB2, also known as Leukocyte immunoglobulin-like receptor subfamily B member 2, has 2 isoforms, a 598 amino acid isoform that is 65 kDa and a 597 amino acid isoform that is approx. 65 kDa; expressed on monocytes and B-cells, and at lower levels on dendritic cells and in natural killer (NK) cells; as a receptor binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response; also competes with CD8A for binding to class I MHC antigens and inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Disease research is currently being performed with relation to LILRB2 and herpes simplex, chronic lymphocytic leukemia, lymphocytic leukemia, and leukemia. Interactions with this protein have been shown to involve PTPN6, FCGR1A, HLA-F, HLA-G, CD1D and other proteins in osteoclast differentiation, immune-regulatory interactions between a lymphoid and a non-lymphoid cell, adaptive immune system, and immune system pathways.